Dose-Ranging Study of an Ophthalamic Solution in Patients With Loss of Visual Function Due to Age-Related Nuclear Cataract

Chakshu Research, Inc.81 enrolled

Overview

This study will evaluate the safety and efficacy of three doses of C-KAD Ophthalmic Solution in patients with loss of visual function due to age-related nuclear cataract

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Nuclear Cataract

Interventions

LiquiTearsDRUG

4 drops applied daily for 360 days

C-KAD Ophthalmic SolutionDRUG

4 drops applied daily for 360 days

C-KAD Ophthalmic SolutionDRUG

4 drops applied daily for 360 days

Eligibility

Sex: ALLMin age: 35 YearsMax age: 90 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Presence of nuclear sclerosis cataract * BCDVA within the range of 20/40 and 20/80 Exclusion Criteria: * Any other clinical condition in the eye that may compromise vision * Presence or history of glaucoma * Presence or history of diabetes * Use of eyedrops * Use of steroids

Locations (1)

Tilganga Eye Center

Kathmandu, Kathmandu, Nepal

Outcomes

Primary Outcomes

Best-corrected visual acuity by ETDRS

Time frame: 360 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.